

# CITATION REPORT

List of articles citing

Review article: proton pump inhibitors and bacterial overgro

DOI: 10.1111/j.1365-2036.2006.02707.x

Alimentary Pharmacology and Therapeutics, 2006, 23, 3-10.

**Source:** <https://exaly.com/paper-pdf/40425673/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
183	Peptic ulcer disease. <b>2006</b> , 22, 607-11		4
182	Current awareness: Pharmacoepidemiology and drug safety. <b>2006</b> , 15, i-xii		
181	Gastric juice--a natural-born killer. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2006</b> , 23, 1677-8; author reply 1678	6.1	
180	Achlorhydria is associated with gastric microbial overgrowth and development of cancer: lessons learned from the gastrin knockout mouse. <b>2006</b> , 66, 607-21		25
179	Microbial colonization of the upper gastrointestinal tract in patients with Barrett's esophagus. <i>Clinical Infectious Diseases</i> , <b>2007</b> , 45, 29-38	11.6	159
178	Action des inhibiteurs de la pompe à protons sur la sécrétion gastrique acide : mécanismes, effets des traitements au long cours. <b>2007</b> , 2, 1-6		1
177	Association between gastric acid suppressants and Clostridium difficile colitis and community-acquired pneumonia: analysis using pharmacovigilance tools. <b>2007</b> , 11, 417-22		16
176	Use of acid-suppressing drugs and the risk of bacterial gastroenteritis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2007</b> , 5, 1418-23	6.9	101
175	Association of proton-pump inhibitors with outcomes in Clostridium difficile colitis. <b>2007</b> , 64, 2359-63		77
174	Vibrio cholerae O1 El Tor cluster in Sydney linked to imported whitebait. <b>2007</b> , 187, 345-7		32
173	Small bowel bacterial overgrowth in adults: a potential contributor to intestinal failure. <i>Current Gastroenterology Reports</i> , <b>2007</b> , 9, 463-7	5	32
172	Pharmacologic management of gastroesophageal reflux disease. <b>2007</b> , 1, 109-113		
171	Control of gastric acid secretion in health and disease. <b>2008</b> , 134, 1842-60		305
170	Do we need gastric acid?. <b>2008</b> , 77, 184-97		30
169	Small intestinal bacterial overgrowth recurrence after antibiotic therapy. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 2031-5	0.7	86
168	Bacterial overgrowth and irritable bowel syndrome: unifying hypothesis or a spurious consequence of proton pump inhibitors?. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 2972-6	0.7	77
167	Proton pump inhibitor use and enteric infections. <i>American Journal of Gastroenterology</i> , <b>2009</b> , 104 Suppl 2, S10-6	0.7	62

166	Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). <b>2009</b> , 49, 498-547		535
165	Proton pump inhibitors: actions and reactions. <b>2009</b> , 14, 647-60		72
164	Acid inhibition and infections outside the gastrointestinal tract. <i>American Journal of Gastroenterology</i> , <b>2009</b> , 104 Suppl 2, S17-20	0.7	24
163	H+/K+ ATPase inhibitors in the treatment of acid-related disorders. <b>2009</b> , 47, 75-162		17
162	Does PPI therapy predispose to Clostridium difficile infection?. <b>2009</b> , 6, 555-7		19
161	Small intestinal bacterial overgrowth in gastroparesis: are there any predictors?. <b>2010</b> , 44, e8-13		43
160	Proton pump inhibitors in the management of GERD. <b>2010</b> , 14 Suppl 1, S62-6		25
159	Proton pump inhibitor therapy does not affect hydrogen production on lactulose breath test in subjects with IBS. <b>2010</b> , 55, 2302-8		28
158	Chronic abdominal pain in children is associated with high prevalence of abnormal microbial fermentation. <b>2010</b> , 55, 124-30		26
157	Small intestinal bacterial overgrowth in irritable bowel syndrome: are there any predictors?. <i>BMC Gastroenterology</i> , <b>2010</b> , 10, 23	3	52
156	Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2010</b> , 31, 1165-77	6.1	123
155	Safety of the long-term use of proton pump inhibitors. <i>World Journal of Gastroenterology</i> , <b>2010</b> , 16, 2323-30	3.0	192
154	Management of gastroesophageal reflux disease and erosive esophagitis in pediatric patients: focus on delayed-release esomeprazole. <b>2010</b> , 6, 531-7		5
153	Association Between Use of Proton Pump Inhibitors and a Clostridium difficile-Associated Disease Outbreak: Case-Control Study. <b>2010</b> , 63, 31-7		6
152	Efficacy of three different dosages of esomeprazole in the long-term management of reflux disease: a prospective, randomized study, using the wireless Bravo pH system. <i>American Journal of Gastroenterology</i> , <b>2010</b> , 105, 308-13	0.7	12
151	Human intestinal microbiota and healthy ageing. <b>2010</b> , 9, 107-16		232
150	Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. <b>2011</b> , 141, 1314-22, 1322.e1-5		318
149	Clinical approach to severe Clostridium difficile infection: update for the hospital practitioner. <b>2011</b> , 22, 561-8		18

148	Effects of long-term PPI treatment on producing bowel symptoms and SIBO. <b>2011</b> , 41, 380-6		83
147	Gastroesophageal Reflux. <b>2011</b> , 232-247.e4		1
146	Health benefits of probiotics: are mixtures more effective than single strains?. <b>2011</b> , 50, 1-17		280
145	Expression of Cckbr, Gast, Reg1&alpha;, Tgfb1 genes in rat pancreas upon long-term hypoacidity and with administration of multiprobiotic «Symbiter® acidophilic» concentrated. <b>2012</b> , 28, 461-467		2
144	The gut microbiota and irritable bowel syndrome: friend or foe?. <b>2012</b> , 2012, 151085		109
143	Is microscopic colitis a drug-induced disease?. <b>2012</b> , 46, 811-22		44
142	Considerations for the use of proton-pump inhibitors in older adults. <b>2012</b> , 27, 114-20		14
141	Natural history of pediatric intestinal failure: initial report from the Pediatric Intestinal Failure Consortium. <b>2012</b> , 161, 723-8.e2		298
140	Increased proton pump inhibitor and NSAID exposure in irritable bowel syndrome: results from a case-control study. <i>BMC Gastroenterology</i> , <b>2012</b> , 12, 121	3	7
139	Potential immunological consequences of pharmacological suppression of gastric acid production in patients with multiple sclerosis. <b>2012</b> , 10, 57		14
138	Proton pump inhibitor therapy predisposes to community-acquired Streptococcus pneumoniae pneumonia. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2012</b> , 36, 941-9	6.1	51
137	Bacterial flora as a cause or treatment of chronic diarrhea. <i>Gastroenterology Clinics of North America</i> , <b>2012</b> , 41, 581-602	4.4	14
136	Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. <i>American Journal of Gastroenterology</i> , <b>2012</b> , 107, 1001-10	0.7	332
135	Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2012</b> , 10, 225-33	6.9	147
134	Gastroesophageal reflux disease in children and adolescents: when and how to treat. <b>2012</b> , 14, 79-89		17
133	Proton pump inhibitor therapy use does not predispose to small intestinal bacterial overgrowth. <i>American Journal of Gastroenterology</i> , <b>2012</b> , 107, 730-5	0.7	76
132	Regulation of Gastric Acid Secretion. <b>2012</b> , 1281-1309		5
131	Stress prophylaxis in intensive care unit patients and the role of enteral nutrition. <b>2012</b> , 36, 721-31		31

130	NSAID gastropathy and enteropathy: distinct pathogenesis likely necessitates distinct prevention strategies. <b>2012</b> , 165, 67-74		104
129	Effect of the proton pump inhibitor omeprazole on the gastrointestinal bacterial microbiota of healthy dogs. <b>2012</b> , 80, 624-36		86
128	Over-prescription of acid-suppressing medications in infants: how it came about, why it's wrong, and what to do about it. <b>2012</b> , 160, 193-8		48
127	Perils and pitfalls of long-term effects of proton pump inhibitors. <b>2013</b> , 6, 443-51		76
126	Helicobacter pylori and the gastric microbiota. <b>2013</b> , 27, 39-45		106
125	Polypharmacy of osteoarthritis: the perfect intestinal storm. <b>2013</b> , 58, 3088-93		34
124	Associations between medication use and functional gastrointestinal disorders: a population-based study. <i>Neurogastroenterology and Motility</i> , <b>2013</b> , 25, 413-9, e298	4	16
123	Clostridium difficile infection in children: a comprehensive review. <b>2013</b> , 29, 967-84		40
122	Association of CYP2C19 polymorphisms and lansoprazole-associated respiratory adverse effects in children. <b>2013</b> , 163, 686-91		35
121	Probiotics and prebiotics and health in ageing populations. <b>2013</b> , 75, 44-50		132
120	Mechanisms, prevention and clinical implications of nonsteroidal anti-inflammatory drug-enteropathy. <i>World Journal of Gastroenterology</i> , <b>2013</b> , 19, 1861-76	5.6	125
119	Letter by Wallace and Chan regarding article, "Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin". <b>2013</b> , 128, e190		1
118	The role of the gastrointestinal microbiome in Helicobacter pylori pathogenesis. <b>2013</b> , 4, 505-31		129
117	Microbial biofilms and gastrointestinal diseases. <b>2013</b> , 67, 25-38		50
116	Microbial Profile of the Stomach: Comparison between Normal Mucosa and Cancer Tissue in the Same Patient. <b>2014</b> , 44, 162		13
115	Does Barrett's esophagus regress after surgery (or proton pump inhibitors)? <b>2014</b> , 32, 156-63		13
114	Environmental and NSAID-enteropathy: dysbiosis as a common factor. <i>Current Gastroenterology Reports</i> , <b>2014</b> , 16, 377	5	14
113	Microbiota in the stomach: new insights. <b>2014</b> , 15, 54-61		35

112	The impact of proton pump inhibitors on the human gastrointestinal microbiome. <b>2014</b> , 34, 771-85		90
111	Pharmacologic options in the management of upper gastrointestinal bleeding: focus on the elderly. <b>2014</b> , 31, 349-61		6
110	NSAID-gastroenteropathy: new aspects of pathogenesis and prevention. <b>2014</b> , 19, 11-6		51
109	Use of proton pump inhibitors and subsequent risk of celiac disease. <b>2014</b> , 46, 36-40		37
108	Eosinophilic esophagitis: interactions with gastroesophageal reflux disease. <i>Gastroenterology Clinics of North America</i> , <b>2014</b> , 43, 243-56	4.4	35
107	Peptic Ulcer Disease. <b>2014</b> , 129-135		
106	Acid suppression therapy and allergic reactions. <b>2015</b> , 24, 25-33		0
105	Acid suppression therapy and allergic reactions. <b>2015</b> , 24, 303-311		12
104	Gut Microbiota: A Modulator of Brain Plasticity and Cognitive Function in Ageing. <b>2015</b> , 3, 898-916		54
103	Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. <i>PLoS ONE</i> , <b>2015</b> , 10, e0128004	3.7	188
102	Systemic Sclerosis: Gastrointestinal Disease and Its Management. <b>2015</b> , 41, 459-73		62
101	The Effect of Proton Pump Inhibitors on Barrett's Esophagus. <i>Gastroenterology Clinics of North America</i> , <b>2015</b> , 44, 415-24	4.4	16
100	The Escherichia coli Acid Stress Response and Its Significance for Pathogenesis. <b>2015</b> , 92, 49-88		36
99	Effect of proton-pump inhibitors on the risk of lower gastrointestinal bleeding associated with NSAIDs, aspirin, clopidogrel, and warfarin. <i>Journal of Gastroenterology</i> , <b>2015</b> , 50, 1079-86	6.9	18
98	Influence of Proton-Pump Inhibitors on the Luminal Microbiota in the Gastrointestinal Tract. <b>2015</b> , 6, e89		91
97	Deciphering the pathogenesis of NSAID enteropathy using proton pump inhibitors and a hydrogen sulfide-releasing NSAID. <b>2015</b> , 308, G994-1003		33
96	Lactobacillus paracasei F19 versus placebo for the prevention of proton pump inhibitor-induced bowel symptoms: a randomized clinical trial. <b>2015</b> , 47, 273-9		10
95	The stomach in health and disease. <b>2015</b> , 64, 1650-68		190

94	Prebiotics and Probiotics in Aging Population. <b>2016</b> , 693-705		
93	Analysis of Gastric Microbiota by Pyrosequencing: Minor Role of Bacteria Other Than <i>Helicobacter pylori</i> in the Gastric Carcinogenesis. <i>Helicobacter</i> , <b>2016</b> , 21, 364-74	4.9	67
92	Efficacy and safety of proton pump inhibitors for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis of randomized trials. <b>2016</b> , 20, 120		69
91	Microscopic Colitis: What Do We Know About Pathogenesis?. <b>2016</b> , 22, 450-8		59
90	Effects of Proton Pump Inhibitors on the Gastric Mucosa-Associated Microbiota in Dyspeptic Patients. <b>2016</b> , 82, 6633-6644		53
89	Eosinophilic Esophagitis: A Relevant Entity for the Otolaryngologist. <b>2016</b> , 67, 167-178		1
88	The Effect of <i>H. pylori</i> Infection on the Gastric Microbiota. <b>2016</b> , 529-533		1
87	Eosinophilic esophagitis: A relevant entity for the otolaryngologist. <b>2016</b> , 67, 167-78		1
86	Mechanisms and therapeutic effectiveness of lactobacilli. <b>2016</b> , 69, 187-203		125
85	Positive regulation of the enzymatic activity of gastric H(+),K(+)-ATPase by sialylation of its $\beta$ subunit. <b>2016</b> , 1858, 1228-35		5
84	Reply to the letter by Kawada entitled "Combined effect of proton-pump inhibitors and other drugs with regard to lower gastrointestinal tract bleeding with special reference to low-dose aspirin". <i>Journal of Gastroenterology</i> , <b>2016</b> , 51, 174-5	6.9	1
83	Multistrain Probiotics. <b>2016</b> , 279-302		1
82	Gastroesophageal Reflux. <b>2016</b> , 105-130		
81	pH-independent immediate release polymethacrylate formulations--an observational study. <i>Drug Development and Industrial Pharmacy</i> , <b>2016</b> , 42, 578-83	3.6	1
80	Prophylaxis for Stress Ulcers With Proton Pump Inhibitors Is Not Associated With Increased Risk of Bloodstream Infections in the Intensive Care Unit. <i>Clinical Gastroenterology and Hepatology</i> , <b>2017</b> , 15, 1030-1036.e1	6.9	6
79	The Esophageal and Gastric Microbiome in Health and Disease. <i>Gastroenterology Clinics of North America</i> , <b>2017</b> , 46, 121-141	4.4	36
78	Impact of the Microbiota and Gastric Disease Development by <i>Helicobacter pylori</i> . <i>Current Topics in Microbiology and Immunology</i> , <b>2017</b> , 400, 253-275	3.3	36
77	GERD Management: The Case for Lifestyle in an Era of PPIs. <i>American Journal of Lifestyle Medicine</i> , <b>2017</b> , 11, 24-28	1.9	0

76	Mucosa-Related Gastropathology: The Upper Gastrointestinal Tract and the Microbiome. <b>2017</b> , 1447-1462		
75	Enlightening discriminative network functional modules behind Principal Component Analysis separation in differential-omic science studies. <i>Scientific Reports</i> , <b>2017</b> , 7, 43946	4.9	35
74	Long-term Use of Proton Pump Inhibitors Is Associated With Increased Microbial Product Translocation, Innate Immune Activation, and Reduced Immunologic Recovery in Patients With Chronic Human Immunodeficiency Virus-1 Infection. <i>Clinical Infectious Diseases</i> , <b>2017</b> , 65, 1638-1643	11.6	4
73	Clinical and surgical factors associated with organ/space surgical site infection after laparoscopic gastrectomy for gastric cancer. <i>Surgical Endoscopy and Other Interventional Techniques</i> , <b>2017</b> , 31, 1667-1674	5.2	10
72	Correlation of Proton Pump Inhibitors with Pulmonary Tuberculosis: A Case-Control Study in Taiwan. <i>Frontiers in Pharmacology</i> , <b>2017</b> , 8, 481	5.6	27
71	Findings in exudates can help distinguish benign gastric ulcers from ulcerated adenocarcinomas. <i>Histopathology</i> , <b>2018</b> , 73, 215-219	7.3	1
70	Proton pump inhibitor medication is associated with colonisation of gut flora in the oropharynx. <i>Acta Anaesthesiologica Scandinavica</i> , <b>2018</b> , 62, 791-800	1.9	6
69	Modulatory activities of <i>Chrysophyllum albidum</i> and its fractions on microflora and colonic pump activities during inflammatory phase of colitis healing in experimental mice. <i>Food Bioscience</i> , <b>2018</b> , 22, 38-49	4.9	2
68	Speculation as to why the Frequency of Eosinophilic Esophagitis Is Increasing. <i>Current Gastroenterology Reports</i> , <b>2018</b> , 20, 26	5	11
67	Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use. <i>Journal of Neurogastroenterology and Motility</i> , <b>2018</b> , 24, 182-196	4.4	95
66	Omeprazole Minimally Alters the Fecal Microbial Community in Six Cats: A Pilot Study. <i>Frontiers in Veterinary Science</i> , <b>2018</b> , 5, 79	3.1	7
65	Gastric bacterial Flora in patients Harboring <i>Helicobacter pylori</i> with or without chronic dyspepsia: analysis with matrix-assisted laser desorption ionization time-of-flight mass spectroscopy. <i>BMC Gastroenterology</i> , <b>2018</b> , 18, 20	3	17
64	Bowel symptoms in patients that receive proton pump inhibitors. Results of a multicenter survey in Mexico. <i>Revista De Gastroenterologia De Mexico (English Edition)</i> , <b>2019</b> , 84, 44-51	0.2	
63	Eosinophilic esophagitis: novel concepts regarding pathogenesis and clinical manifestations. <i>Journal of Gastroenterology</i> , <b>2019</b> , 54, 837-844	6.9	11
62	Proton pump inhibitors therapy and the risk of pneumonia: a systematic review and meta-analysis of randomized controlled trials and observational studies. <i>Expert Opinion on Drug Safety</i> , <b>2019</b> , 18, 163-172	4.1	30
61	Gastroesophageal Reflux in the Child with Cerebral Palsy. <b>2019</b> , 1-15		
60	Microbiota and gastrointestinal cancer. <i>Journal of the Formosan Medical Association</i> , <b>2019</b> , 118 Suppl 1, S32-S41	3.2	34
59	Gastroöophageale Refluxkrankheit. <i>Journal Fuer Gastroenterologische Und Hepatologische Erkrankungen</i> , <b>2019</b> , 17, 28-37	0	



58	Dietary nitrate supplementation alters the oral microbiome but does not improve the vascular responses to an acute nitrate dose. <i>Nitric Oxide - Biology and Chemistry</i> , <b>2019</b> , 89, 54-63	5	29
57	The relationship between gastric microbiota and gastric disease. <i>Scandinavian Journal of Gastroenterology</i> , <b>2019</b> , 54, 391-396	2.4	17
56	Impact factors that modulate gastric cancer risk in Helicobacter pylori-infected rodent models. <i>Helicobacter</i> , <b>2019</b> , 24, e12580	4.9	6
55	The Gastric Microbiome in Benign and Malignant Diseases. <b>2019</b> , 101-108		
54	Gastric Microbiota: Between Health and Disease. <b>2019</b> ,		
53	Virulence Factors Exploiting Gastric Colonization and its Pathogenicity. <i>Toxins</i> , <b>2019</b> , 11,	4.9	64
52	Helicobacter pylori antibody and pepsinogen testing for predicting gastric microbiome abundance. <i>PLoS ONE</i> , <b>2019</b> , 14, e0225961	3.7	4
51	Systemic sclerosis. <b>2019</b> , 291-329		
50	Evaluation of gastric microbiome and metagenomic function in patients with intestinal metaplasia using 16S rRNA gene sequencing. <i>Helicobacter</i> , <b>2019</b> , 24, e12547	4.9	39
49	Novel Implementation of Genotype-Guided Proton Pump Inhibitor Medication Therapy in Children: A Pilot, Randomized, Multisite Pragmatic Trial. <i>Clinical and Translational Science</i> , <b>2019</b> , 12, 172-179	4.9	14
48	Bowel symptoms in patients that receive proton pump inhibitors. Results of a multicenter survey in Mexico. <i>Revista De Gastroenterología De México</i> , <b>2019</b> , 84, 44-51	0.7	8
47	Bacterial colonization of the stomach and duodenum in a Swedish population with and without proton pump inhibitor treatment. <i>JGH Open</i> , <b>2020</b> , 4, 405-409	1.8	2
46	The Role of Gastric Mucosal Immunity in Gastric Diseases. <i>Journal of Immunology Research</i> , <b>2020</b> , 2020, 7927054	4.5	8
45	Early Life Risk Factors in Pediatric EoE: Could We Prevent This Modern Disease?. <i>Frontiers in Pediatrics</i> , <b>2020</b> , 8, 263	3.4	10
44	Emerging incidence trends of eosinophilic esophagitis over 25 years: Results of a nationwide register-based pathology cohort. <i>Neurogastroenterology and Motility</i> , <b>2021</b> , 33, e14072	4	4
43	Gastroesophageal Reflux. <b>2021</b> , 212-229.e6		0
42	The Role of Gut Microbiota Dysbiosis in Gastrointestinal Carcinogenesis. <b>2021</b> ,		
41	Nonlinear machine learning pattern recognition and bacteria-metabolite multilayer network analysis of perturbed gastric microbiome. <i>Nature Communications</i> , <b>2021</b> , 12, 1926	17.4	7

40	A Rare Case of Delayed Perigastric Abscess after Curative Resection of Early Gastric Cancer by Uncomplicated Endoscopic Submucosal Dissection: Successful Treatment with Endoscopic Ultrasound-guided Drainage. <i>Internal Medicine</i> , <b>2021</b> , 60, 1383-1387	1.1	1
39	Antireflux and Endoscopic Therapies for Barrett Esophagus and Superficial Esophageal Neoplasia. <i>Surgical Clinics of North America</i> , <b>2021</b> , 101, 391-403	4	1
38	Propionibacterium acnes overabundance in gastric cancer promote M2 polarization of macrophages via a TLR4/PI3K/Akt signaling. <i>Gastric Cancer</i> , <b>2021</b> , 24, 1242-1253	7.6	8
37	Association between proton pump inhibitors and periodontal disease severity. <i>Clinical and Experimental Dental Research</i> , <b>2021</b> ,	1.9	2
36	Irritable Bowel Syndrome. 1495-1521		1
35	Systemic Sclerosis. <b>2013</b> , 955-969		1
34	Gastric Secretion. <b>2010</b> , 817-832.e7		2
33	Meta-analysis of proton pump inhibitors induced risk of community-acquired pneumonia. <i>International Journal for Quality in Health Care</i> , <b>2020</b> , 32, 292-299	1.9	10
32	Inflammation, atrophy, and gastric cancer. <i>Journal of Clinical Investigation</i> , <b>2007</b> , 117, 60-9	15.9	544
31	Probiotics and Prebiotics in Elderly Individuals. <b>2009</b> ,		6
30	Use of Proton Pump Inhibitors and the Risk of Hospitalization for Infectious Gastroenteritis. <i>PLoS ONE</i> , <b>2016</b> , 11, e0168618	3.7	12
29	Proton Pump Inhibitors Did Not Increase Risk of Pneumonia in Patients With Chronic Obstructive Pulmonary Disease. <i>Journal of Clinical Medicine Research</i> , <b>2015</b> , 7, 880-3	2.9	10
28	Influence of oxidative stress on the level of genes expression TGFB1 and HGF in rat liver upon long-term gastric hypochlorhydria and administration of multiprobiotic Symbiter. <i>Ukrainian Biochemical Journal</i> , <b>2013</b> , 85, 114-123	0.7	10
27	Predisposing factors for positive D-Xylose breath test for evaluation of small intestinal bacterial overgrowth: a retrospective study of 932 patients. <i>World Journal of Gastroenterology</i> , <b>2015</b> , 21, 4574-82	5.6	15
26	Potential Strategies in the Prevention of Nonsteroidal Anti-inflammatory Drugs-Associated Adverse Effects in the Lower Gastrointestinal Tract. <i>Gut and Liver</i> , <b>2020</b> , 14, 179-189	4.8	16
25	Atrophy and Altered Mesenchymal-Epithelial Signaling Preceding Gastric Cancer. <b>2009</b> , 449-482		1
24	Acid Inhibition and Infections Outside the Gastrointestinal Tract. <i>American Journal of Gastroenterology</i> , <b>2009</b> , 104, S17-S20	0.7	
23	Proton Pump Inhibitor Use and Enteric Infections. <i>American Journal of Gastroenterology</i> , <b>2009</b> , 104, S10-S16		

22	Bacterial Overgrowth. <b>2010</b> , 189-207		0
21	A Case of Collagenous Colitis Causing Alimentary Canal Puncture. <i>Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association)</i> , <b>2013</b> , 74, 3082-3086		0
20	Changes of energy balance of rat liver and pancreas upon gastric hypoacidity and search of approaches for its recovery. <i>Bulletin of Taras Shevchenko National University of Kyiv Series Biology</i> , <b>2014</b> , 68, 54-57		0.2
19	Microflora of upper gastrointestinal tract in gastric cancer patients. <i>Korean Journal of Clinical Oncology</i> , <b>2015</b> , 11, 87-94		0.1
18	Which Gastric Microbiota Associated with <i>Helicobacter pylori</i> in Dyspeptic Patients with Gastritis. <i>Open Journal of Gastroenterology</i> , <b>2018</b> , 08, 425-433		0.2 0
17	Bacteriologic Evaluation of Ventilator-Associated Pneumonia According to Stress Related Mucosal Disease Prophylaxis in the Intensive Care Unit. <i>Archives of Clinical Infectious Diseases</i> , <b>2018</b> , 13,		3.1
16	Antioxidant protection enzyme activity in the blood serum and large intestinal mucosa of rats with prolonged gastric hypochlorhydria and given multiprobitotics. <i>Regulatory Mechanisms in Biosystems</i> , <b>2020</b> , 10, 438-444		0.7
15	Gastroesophageal Reflux in the Child with Cerebral Palsy. <b>2020</b> , 751-765		
14	Machine learning pattern recognition and differential network analysis of gastric microbiome in the presence of proton pump inhibitor treatment or <i>Helicobacter pylori</i> infection.		
13	Bakterielle Berbesiedlung. <b>2006</b> , 277-285		
12	The bacterial association with oral cavity and intra-abdominal abscess after gastrectomy. <i>PLoS ONE</i> , <b>2020</b> , 15, e0242091		3.7 1
11	The impact of acid-suppressing drugs to the patients with chronic obstructive pulmonary disease: A nationwide, population-based, cohort study. <i>Journal of Research in Medical Sciences</i> , <b>2015</b> , 20, 263-7		1.6 6
10	Association Between Proton Pump Inhibitor Exposure and Infection in Elderly, Hospitalized Patients. <i>Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS</i> , <b>2015</b> , 32, 21-25		0.7
9	The role of non- bacteria in the development of gastric cancer. <i>American Journal of Cancer Research</i> , <b>2020</b> , 10, 2271-2281		4.4 3
8	Gastroesophageal Reflux. <b>2022</b> , 125-155		
7	Complex Interplay of Heme-Copper Oxidases with Nitrite and Nitric Oxide.. <i>International Journal of Molecular Sciences</i> , <b>2022</b> , 23,		6.3 0
6	Table_1.PDF. <b>2018</b> ,		
5	Antibiotic and antifungal use in pediatric leukemia and lymphoma patients are associated with increasing opportunistic pathogens and decreasing bacteria responsible for activities that enhance colonic defense. <i>Frontiers in Cellular and Infection Microbiology</i> , 12,		5.9 0

- |   |   |   |
|---|---|---|
| 4 | Use of digital pathology and artificial intelligence for the diagnosis of <i>Helicobacter pylori</i> in gastric biopsies. <b>2022</b> , 114, 295-303                | 0 |
| 3 | Proton pump inhibitor usage associates with higher risk of first episodes of pneumonia and peritonitis in peritoneal dialysis patients. <b>2022</b> , 44, 1623-1631 | 0 |
| 2 | Proton pump inhibitors: Are they safe?. <b>2022</b> , 13, 34-47   | 1 |
| 1 | Oral omeprazole and diclofenac intake is associated with increased faecal calprotectin levels: a randomised open-label clinical trial. <b>2023</b> , 35, 52-58      | 0 |